These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 4961775)

  • 1. Value of serum viscosity measurements in assessing the response to therapy in myeloma and Waldenström's macroglobulinaemia.
    Kok DA
    Bibl Anat; 1967; 9():252-8. PubMed ID: 4961775
    [No Abstract]   [Full Text] [Related]  

  • 2. Appropriateness of applying the response criteria for multiple myeloma to Waldenstrom's macroglobulinemia?
    Bladé J; Montoto S; Rosiñol L; Montserrat E
    Semin Oncol; 2003 Apr; 30(2):329-31. PubMed ID: 12720163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy of macroglobulinaemia. Comparison of the effect of therapy on the level of monoclonal immunoglobulins and on clinical symptoms in four cases of waldenström's macroglobulinaemia and one case of IgA myeloma.
    Pronk EA; Elkerbout F; Klein F; Radema H; Cleton FJ
    Acta Med Scand; 1969 Oct; 186(4):273-81. PubMed ID: 4190857
    [No Abstract]   [Full Text] [Related]  

  • 4. On the aggregation of red cells in Waldenström's macroglobulinaemia and multiple myeloma.
    Dintenfass L; Somer T
    Microvasc Res; 1975 May; 9(3):279-86. PubMed ID: 805345
    [No Abstract]   [Full Text] [Related]  

  • 5. Plasma volume expansion and increased serum viscosity in myeloma and macroglobulinaemia.
    Tuddenham EG; Bradley J
    Clin Exp Immunol; 1974 Feb; 16(2):169-76. PubMed ID: 4219875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Present state of therapy of myeloma and Waldenström's macroglobulinemic lymphoreticulosis].
    Grifoni V; Bignotti G; Tognella S; Scaltrini G
    Recenti Prog Med; 1965 Oct; 39(4):415-36. PubMed ID: 4955116
    [No Abstract]   [Full Text] [Related]  

  • 7. [Current treatment of Kahler's disease and Waldenström's macroglobulinemia].
    Seligmann M; Meshaka G
    Sem Ther; 1965; 41(6):373-5. PubMed ID: 4964847
    [No Abstract]   [Full Text] [Related]  

  • 8. Increased plasma viscosity as a reason for inappropriate erythropoietin formation.
    Singh A; Eckardt KU; Zimmermann A; Götz KH; Hamann M; Ratcliffe PJ; Kurtz A; Reinhart WH
    J Clin Invest; 1993 Jan; 91(1):251-6. PubMed ID: 8423222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of Waldenström's macroglobulinaemia with procarbazine].
    Mitrou P; Schubert JC; Martin H
    Dtsch Med Wochenschr; 1972 Dec; 97(48):1864. PubMed ID: 4629116
    [No Abstract]   [Full Text] [Related]  

  • 10. [Waldenström's macroglobulinemia].
    Meznik A; Steppert A
    Wien Med Wochenschr; 1968 Jun; 118(23):523-31. PubMed ID: 4977674
    [No Abstract]   [Full Text] [Related]  

  • 11. [Neurologic manifestations in the course of monoclonal gammopathies. Review of the literature and description of 5 cases of multiple myeloma and 2 cases of Waldenstrom's macroglobulinemia with various involvements of the nervous system].
    Azzena D; Ghigliotti G; Astengo F; Costa U; Molinelli G
    Haematologica; 1967; 52(12):999-1031. PubMed ID: 4974264
    [No Abstract]   [Full Text] [Related]  

  • 12. A hypothesis of plasma "atomosphere" around the red cells in patients with Waldenström's macroglobulinemia and multiple myeloma: A deduction from viscosity study.
    Dintenfass L; Somer T
    Microvasc Res; 1976 May; 11(3):325-34. PubMed ID: 819759
    [No Abstract]   [Full Text] [Related]  

  • 13. Hepatocellular carcinoma followed by Waldenström's macroglobulinemia: a case report.
    Hasegawa K; Kubota K; Hirai H; Imai Y; Midorikawa Y; Makuuchi M
    Hepatogastroenterology; 2000; 47(33):842-5. PubMed ID: 10919044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum and urine light chain levels in benign monoclonal gammapathies, multiple myeloma and Waldenström's macroglobulinaemia.
    Dammacco F; Waldenström J
    Clin Exp Immunol; 1968 Nov; 3(9):911-21. PubMed ID: 4180117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Trial of combination chemotherapy for multiple myeloma and macroglobulinemia--VENAP therapy (author's transl)].
    Furukawa K; Fujiwara Y; Nakaide Y; Tanaka M; Tanaka M; Hirota Y
    Rinsho Ketsueki; 1980 Nov; 21(11):1683-91. PubMed ID: 6782278
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effect of intensive plasmapheresis on the "syndrome of increased viscosity" and blood coagulation system in Waldenstrom's macroglobulinemia].
    Mokeeva RA; Zhuravlev VS
    Probl Gematol Pereliv Krovi; 1969 Mar; 14(3):8-16. PubMed ID: 4981700
    [No Abstract]   [Full Text] [Related]  

  • 17. [The blood coagulation system in patients with Waldenstrom's macroglobulinemia and multiple myeloma].
    Kokeva RA; Zhuravlev VS
    Probl Gematol Pereliv Krovi; 1968 Jun; 13(6):10-5. PubMed ID: 4981865
    [No Abstract]   [Full Text] [Related]  

  • 18. Recent advances in treatment of multiple myeloma and Waldenström's macroglobulinemia.
    Alexanian R; Weber D
    Biomed Pharmacother; 2001 Nov; 55(9-10):550-2. PubMed ID: 11769965
    [No Abstract]   [Full Text] [Related]  

  • 19. Protein SAP (serum amyloid P-component) in Waldenström's macroglobulinaemia, multiple myeloma and rheumatic diseases.
    Strachan AF; Johnson PM
    J Clin Lab Immunol; 1982 Sep; 8(3):153-6. PubMed ID: 6813503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood volume and hematocrit value in macroglobulinemia and myeloma.
    Kopp WL; MacKinney AA; Wasson G
    Arch Intern Med; 1969 Apr; 123(4):394-6. PubMed ID: 4976452
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.